Skip to main content
EMYRIA LIMITED logo

EMYRIA LIMITED — Investor Relations & Filings

Ticker · EMD ISIN · AU0000073645 LEI · 529900IMZL1QU98KGH07 ASX Professional, scientific and technical activities
Open in API
Filings indexed 441 across all filing types
Latest filing 2023-07-02 Capital/Financing Update
Country AU Australia
Listing ASX EMD

About EMYRIA LIMITED

https://emyria.com

Emyria Limited is a clinical-stage biotechnology company focused on developing and delivering new treatments for mental health and neurological conditions. The company integrates clinical service delivery with data-driven drug development to accelerate the path to market for novel therapies. Emyria operates a network of specialist clinics that provide evidence-based care while collecting high-quality real-world data to inform its drug discovery pipeline. Key focus areas include MDMA-assisted therapy for post-traumatic stress disorder (PTSD) and the development of proprietary cannabinoid-based medicines. Through its partnership with clinical research organizations and mental health specialists, the company aims to provide scalable, data-backed solutions for complex health challenges. Its proprietary data platform supports the identification of new drug targets and the optimization of clinical trial designs.

Recent filings

Filing Released Lang Actions
Pax Centre Acquisition to Advance Psychedelic Therapies 8 pages 1.2MB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated July 3, 2023, detailing the strategic acquisition of the Pax Centre by Emyria Limited. It discusses the acquisition terms, strategic rationale, operational synergies, and future plans related to mental health services and psychedelic-assisted therapy. The content focuses on the acquisition transaction, including consideration, conditions precedent, and integration plans. There are no financial statements, quarterly or annual results, nor is this a transcript of a call or a regulatory compliance filing. The document is clearly an announcement of a capital transaction (acquisition) and not a full report or financial statement. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support a high confidence in this classification.
2023-07-02 English
Proposed issue of securities - EMD 5 pages 28.2KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Emyria Limited regarding a proposed issue of securities, specifically a placement of 10,236,200 ordinary fully paid shares. It details the terms, conditions, and timetable of the proposed issue, including escrow arrangements and regulatory compliance under ASX Listing Rules. The content focuses on the capital raising activity and issuance of new shares rather than financial results, management changes, or other report types. The document is about a financing activity and capital structure change, fitting the Capital/Financing Update category.
2023-07-02 English
Trading Halt 2 pages 388.4KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Emyria Limited regarding a trading halt requested under ASX Listing Rule 17.1. It states that the halt is pending the release of an announcement about a strategic acquisition related to the company's psychedelic-assisted therapy program. The document does not contain financial data, detailed report content, or results but is an official notice about a trading halt. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like M&A filings or capital updates since it only announces the halt pending a future announcement.
2023-06-28 English
Emyria Receives Ethics Approval for MDMA-assisted Therapy 4 pages 736.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 08 June 2023 from Emyria Limited. It discusses the receipt of ethics approval for a clinical trial involving MDMA-assisted therapy for PTSD, details about the trial, partnerships, regulatory changes, and the company's drug development programs. The content is focused on clinical trial initiation, regulatory and ethical approvals, and business updates rather than financial results or detailed financial statements. It is not a full annual or interim report, nor an earnings release or audit report. It is a corporate announcement about a clinical trial and related business developments. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and corporate updates that do not fit other specific categories.
2023-06-07 English
Notification regarding unquoted securities - EMD 9 pages 34.1KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed notification regarding the issue of unquoted equity securities (options) by Emyria Limited. It includes specifics such as the number of securities issued, exercise price, expiry date, and references to ASX announcements and Appendix 3B filings. The content focuses on the issuance of new securities, placement details, and compliance with ASX listing rules. There is no indication of financial statements, audit information, management commentary, or earnings data. The document is not a report but an announcement of a securities issuance event. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement but a formal notification of a capital change event.
2023-05-09 English
Application for quotation of securities - EMD 8 pages 30.2KB
Capital/Financing Update Classification · 100% confidence The document is an application for quotation of securities by Emyria Limited, detailing the number and type of securities to be quoted on the ASX, issue dates, and related placement details. It references a previous Appendix 3B announcement about the securities issuance. The content focuses on the listing and quotation of new shares following a placement to raise capital. There are no financial statements, management discussion, or audit information present. This type of document is a formal announcement related to capital raising and securities quotation, fitting the category of Capital/Financing Update (CAP).
2023-05-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.